Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says. Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Cigna Group’s drug benefit unit is offering ... cash price for Eli Lilly & Co.’s Zepbound or Novo Nordisk A/S’s Wegovy, but typically more than the normal copay. Meanwhile, health plans ...

NEW YORK (Reuters) -Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans ...

While Cigna would not discuss the actual discounts ... gotten between 30% to 50% below the drugs' list price. While Novo's Wegovy lists for $1,350 per month, in March the average net price for ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not ...